跳转至内容
Merck
CN

L5545

Levosimendan

≥98% (HPLC), calcium sensitizer, powder

别名:

(-)-OR-1259, (R)-Simendan, 2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile, OR 1259, R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C14H12N6O
化学文摘社编号:
141505-33-1
分子量:
280.28
UNSPSC Code:
12352202
PubChem Substance ID:
329817628
NACRES:
NA.77
MDL number:
MFCD00867135

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Levosimendan, ≥98% (HPLC)

SMILES string

C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2

InChI key

WHXMKTBCFHIYNQ-SECBINFHSA-N

InChI

1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -500 to -650°, c = 0.5 in THF

color

yellow

solubility

DMSO: ≥20 mg/mL

storage temp.

room temp

Quality Level

100

Gene Information

human ... PDE3A(5139), PDE3B(5140), TNNC1(7134), TNNI3(7137), TNNT2(7139)

相关类别

Application

Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property. It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines

Biochem/physiol Actions

Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.
Levosimendan is a calcium sensitiser.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000523222
0000523222
0000472405
0000472405
0000449431

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Matti Adam et al.
Scientific reports, 5, 9704-9704 (2015-04-14)
Treatment of decompensated heart failure often includes administration of levosimendan. Myeloperoxidase (MPO) is released during polymorphonuclear neutrophil (PMN) degranulation, and mediates dysregulation of vascular tone in heart failure. We evaluated the effects of levosimendan-treatment on MPO in patients with acute
Claes-Håkan Bergh et al.
European journal of heart failure, 12(4), 404-410 (2010-03-26)
The aim of this study is to compare the effects of a 24 h intravenous infusion of levosimendan and a 48 h infusion of dobutamine on invasive haemodynamics in patients with acutely decompensated chronic NYHA class III-IV heart failure. All
Saraswati Kache et al.
Pediatric research, 88(5), 705-716 (2020-07-08)
Fewer children than adults have been affected by the COVID-19 pandemic, and the clinical manifestations are distinct from those of adults. Some children particularly those with acute or chronic co-morbidities are likely to develop critical illness. Recently, a multisystem inflammatory
Malin Johansson et al.
Journal of cardiothoracic and vascular anesthesia, 28(4), 960-965 (2013-12-10)
The aim of the present study was to evaluate acute kidney injury (AKI) with cystatin C following transcatheter aortic valve implantation (TAVI) and to assess the impact of postoperative AKI on outcome and late renal function. A prospective study. Single
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription
Hayashi T, et al.
Antiviral research, 146, 76-85 (2017)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持